Skip to main content
Clinical Trials/NCT01637805
NCT01637805
Unknown
Phase 1

Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With CEA Gene in Stage IV Gastric Cancer

Tianjin Medical University Cancer Institute and Hospital1 site in 1 country30 target enrollmentMay 2012

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Stage IV Gastric Cancer
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment
30
Locations
1
Primary Endpoint
Objective response rate
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the clinical safety and preliminary efficacy of antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene in the treatment of stage IV gastric cancer patients.

Registry
clinicaltrials.gov
Start Date
May 2012
End Date
December 2016
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Sex: male or female
  • Age: from 18 to 80 years
  • Histology: gastric cancer
  • Clinical stage: stage IV
  • Karnofsky performance status: more than 50%
  • Expected survival: more than 2 months
  • Sex: male or female
  • Laboratory tests results 7 days before the start of treatment:
  • White blood cells: more than 3.0 × 109/L
  • Platelets: more than 100 × 109/L

Exclusion Criteria

  • History of neoplasms: other neoplasms
  • Medical history: mental disease, or congestive heart failure, or severe coronary artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy
  • Metastasis: clinical symptoms of brain metastasis
  • Other clinical trial: the subject received other clinical trial before this study
  • Laboratory tests: the serum test of human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus was positive
  • Woman: pregnant or lactating women
  • Compliance: poor compliance

Outcomes

Primary Outcomes

Objective response rate

Time Frame: Up to 12 months

CR + PR = ORR

Study Sites (1)

Loading locations...

Similar Trials